Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Consumer Defensive · Tobacco

Turning Point Brands, Inc. logoTurning Point Brands, Inc.

TPB · the NYSE · USD · Market cap $1.2B · 484 employees

Turning Point Brands, Inc., together with its subsidiaries, manufactures, markets, and distributes branded consumer products in the United States and Canada.

FAIL · Does not pass the screen
49.51 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price49.51 USD at the 17 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 17 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 3.19)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $81.00 to $95.12, base estimate $82.72 (screen dated 2026-11-17).

Current read
Distribution ?
Undervalued · screened 2026-11-17
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 3.19, read 2026-11-15
  • Ethical does not pass the values gate
Price49.51 USD
Fair value82.72
Ethical score30.0/100
Value readUndervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-11-16Read Distribution55.55-10.9% to today ✓Markup gives way to Distribution after a 17% slide in 2 weeks
2026-11-01Read Markup67.31-26.4% to today Distribution gives way to Markup after a 12% rise in 4 weeks
2026-10-02Read Distribution60.12-17.6% to today ✓Markdown gives way to Distribution after a 20% slide in 2 weeks
2026-09-15Read Markdown75.22-34.2% to today ✓Distribution gives way to Markdown after a 9% slide in 4 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Turning Point Brands, Inc. holds its Distribution at $49.51. The statistical read favours the buyers, held for 34 days.

As held on the ledger · 2026-11-17
PhaseDistribution · caution
Quantitative stateThe statistical read favours the buyers, held for 34 days
Price at the screen$49.51
Valuation27.27 trailing · 28.16 forward price to earnings
Values screenFAIL · score 30.0
Beta1.09
The Workings

Five Screens, Shown in Full

Does not pass. Prohibited business activity: Tobacco

TestFigureLimitWhat it meansStatus
Business activity Excluded Core business clean Prohibited business activity: Tobacco Fail
Debt load Excluded Below 33% Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash Excluded Below 33% Interest-bearing cash and securities are of assets, above the one-third limit. Fail
Receivables Excluded Below 49% Money owed to the company is of assets, above the 49% limit. Fail
Revenue purity Excluded Below 5% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Turning Point Brands, does not clear the screen at the business-activity stage. It operates in tobacco, so the financial ratios are not the deciding factor here.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when TPB's ethical verdict changes

Today TPB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 40% discount to our $82.72 fair value, 22.60% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

81.00Conservative82.72Base case95.12Growth case 49.51Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 40.1% discount to the base estimate.

The Street's Range
90.00Street low 120.50Street average 140.00Street high 49.51Price

Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +143% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $82.72, with a range of $81.00 to $95.12, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Tobacco maker clears hurdles yet fails the screen

Picture a smoker in a small town reaching for familiar rolling papers or chewing tobacco at the counter. Those steady purchases keep Turning Point Brands growing revenue at 17 percent with a 12 percent profit margin and 23 percent return on equity. The numbers look solid on paper and the shares trade below the analyst median target, yet the business sits squarely in prohibited tobacco activity.

We pass for one clear reason. The ethical screen exists to keep us out of sectors that profit directly from harmful products, regardless of growth rates or margins. Forward earnings sit at 29 times and the moat remains unknown, but none of that matters once the screen flags the core activity.

Risk here is straightforward. Tobacco faces rising regulation, litigation and shifting consumer habits that can compress volumes quickly. The margin of safety versus our fair value offers little protection when the entire category carries permanent ethical exclusion. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E28.2xpriced for continued growth
Trailing P/E27.3xa premium valuation
EPS, trailing2.32
EPS, forward2.25
Revenue growth+22.6%strong top-line growth
Profit margin8.8%thin but positive margins
Return on equity17.6%a solid return on shareholder capital
FCF yield-0.67%
Dividend yield0.35%
Debt to equity0.68moderate, manageable leverage
Current ratio5.67comfortably covers its short-term bills
Beta1.09moves a little more than the market
Short interest, float0.17%
52-week range54.17 - 146.90
Market cap$1.2B
Employees484

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

TPB trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-16 Distribution · changed $55.55 -15.7% Entry 18

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130.

2026-11-09 Markup $65.88 +0.0% Entry 17

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-08 Markup $65.88 +0.0% Entry 16

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-07 Markup $65.88 -2.4% Entry 15

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-06 Markup $67.47 -4.2% Entry 14

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-05 Markup $70.40 +4.6% Entry 13

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-04 Markup $67.29 0.0% Entry 12

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Markup $67.31 +0.0% Entry 11

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-02 Markup $67.31 +0.0% Entry 10

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Markup · changed $67.31 +16.7% Entry 9

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. Since the last review it its composite score eased.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on TPB

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in TPB's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $92.71 -13.6% · $864 -13.6%
2 months $83.56 -4.2% · $958 -4.2%
3 months $88.88 -9.9% $0.08 $902 -9.8%
6 months $104.48 -23.4% $0.16 $768 -23.2%
1 year $73.55 +8.9% $0.31 $1,093 +9.3%
2 years $31.30 +155.9% $0.59 $2,577 +157.7%
3 years $22.05 +263.2% $0.86 $3,671 +267.1%
5 years $43.42 +84.5% $1.33 $1,875 +87.5%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever TPB does next, these words stay.

Turning Point Brands, Inc. · TPB · Distribution · $49.51
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.